Total | Locoregional recurrence | Distant metastasis | p-value | |
---|---|---|---|---|
(n = 107) | (n = 66) | (n = 41) | ||
Age, years (IQR) | 60.2 (58.5–62.1) | 60.5 (58.2–62.9) | 59.9 (57.0–62.7) | 0.710 |
Sex | 0.289 | |||
 Male | 100 (93.5%) | 63 (95.5%) | 37 (90.2%) | |
 Female | 7 (6.5%) | 3 (5.0%) | 4 (9.8%) | |
Smoking | 0.712 | |||
 Former or current | 65 (60.7%) | 41 (62.1%) | 24 (58.5%) | |
 Never | 42 (39.3%) | 25 (37.9%) | 17 (41.5%) | |
Betel nuts | 0.264 | |||
 Former or current | 89 (83.2%) | 57 (86.4%) | 32 (78.0%) | |
 Never | 18 (16.8%) | 9 (13.6%) | 9 (22.0%) | |
Performance status | 0.110 | |||
 ECOG = 0 | 71 (66.3%) | 40 (60.6%) | 31 (75.6%) | |
 ECOG≧1 | 36 (33.6%) | 26 (39.4%) | 10 (24.4%) | |
Primary tumor location | 0.043¢ | |||
 Oral cavity | 54 (50.5%) | 40 (60.6%) | 14 (34.1%) | |
 Oropharynx | 19 (17.8%) | 7 (10.6%) | 12 (29.3%) | |
 Hypopharynx | 22 (20.6%) | 11 (16.7%) | 11 (26.8%) | |
 Larynx | 9 (8.4%) | 6 (9.1%) | 3 (7.3%) | |
 Other sites†| 3 (2.8%) | 2 (3.0%) | 1 (2.4%) | |
Differentiation of tumor | 0.248 | |||
 Well to moderate | 68 (63.5%) | 38 (57.6%) | 30 (73.2%) | |
 Poor | 9 (8.4%) | 6 (9.1%) | 3 (7.3%) | |
 Not available | 30 (28.0%) | 22 (33.3%) | 8 (19.5%) | |
Previous systemic treatments | 0.086 | |||
 Neoadjuvant chemotherapy | 40 (37.4%) | 27 (31.8%) | 13 (25.0%) | |
 Primary CCRT | 47 (43.9%) | 33 (38.8%) | 14 (26.9%) | |
 Adjuvant CCRT | 50 (46.7%) | 25 (29.4%) | 25 (48.1%) | |
Treatment after recurrence | 0.663 | |||
 EXTREME regimenγ | 68 (63.6%) | 43 (65.2%) | 25 (61.0%) | |
 Salvage surgery | 14 (21.2%) | 14 (21.2%) | – | |
 Reirradiation | 15 (22.7%) | 15 (22.7%) | – | |
Recurrence after RT | 0.035 | |||
  <  6 months | 50 (46.7%) | 37 (56.1%) | 13 (31.7%) | |
 ≧ 6 months | 49 (45.8%) | 26 (39.4%) | 23 (56.1%) | |
 Not available | 8 (7.5%) | 3 (4.5%) | 5 (12.2%) |